Selective estrogen receptor modulators as brain therapeutic agents.
Selective estrogen receptor modulators (SERMs), used for the treatment of breast cancer, osteoporosis, and menopausal symptoms, affect the nervous system. Some SERMs trigger neuroprotective mechanisms and reduce neural damage in different experimental models of neural trauma, brain inflammation, neurodegenerative diseases, cognitive impairment, and affective disorders. New SERMs with specific actions on neurons and glial cells may represent promising therapeutic tools for the brain.
Instituto Cajal, CSIC, Avenida Doctor Arce 37, E-28002 Madrid, Spain.
María Angeles
MA
Arevalo
María
M
Santos-Galindo
Natalia
N
Lagunas
Iñigo
I
Azcoitia
Luis M
LM
Garcia-Segura
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001927:Brain Diseases / Q000188:drug therapy* / Q000378:metabolism; D001930:Brain Injuries / Q000188:drug therapy; D004660:Encephalitis / Q000188:drug therapy; D006801:Humans; D019964:Mood Disorders / Q000188:drug therapy; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
D018696:Neuroprotective Agents; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride